参考文献/References:
[1] Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein(LDL)receptor and LDL cholesterol[J]. J Biol Chem,2004,279(47):48865-48875.
[2] Seidah NG, Awan Z, Chrétien M, et al. PCSK9: a key modulator of cardiovascular health[J]. Circ Res, 2014,114(6):1022-1036.
[3] Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9(PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration[J]. Hepatology,2008,48(2):646-654.
[4] Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters[J]. J Lipid Res,2010,51(6):1486-1495.
[5] Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine[J]. J Biol Chem,2009,284(42):28885-28895.
[6] Berger JM, Vaillant N, le May C,et al. PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension[J]. Atherosclerosis,2015,239(1):252-259.
[7] lo Surdo P, Bottomley MJ, Calzetta A, et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH[J]. EMBO Rep, 2011,12(12):1300-1305.
[8] Tveten K, Holla ØL,Cameron J, et al. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification[J]. Hum Mol Genet,2012,21(6):1402-1409.
[9] Poirier S,Mayer G,Poupon V,et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation:evidence for an intracellular route[J]. J Biol Chem,2009,284(42):28856-28864.
[10] Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest,2006,116(11):2995-3005.
[11] Liu M, Wu G, Baysarowich J, et al. PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain[J]. J Lipid Res,2010,51(9):2611-2618.
[12] Rousselet E, Marcinkiewicz J, Kriz J, et al. PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke[J]. J Lipid Res,2011,52(7):1383-1391.
[13] Lagace TA, Curtis DE, Garuti R,et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest,2006,116(11): 2995-3005.
[14] Rashid S,Curtis DE,Garuti R,et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9[J]. Proc Natl Acad Sci USA,2005,102(15):5374-5379.
[15] Frank-Kamenetsky M, Grefhorst A, Anderson NN,et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates[J]. Proc Natl Acad Sci USA,2008,105(33):11915-11920.
[16] Graham MJ, Lemonidis KM, Whipple CP,et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice[J]. J Lipid Res,2007,48(4): 763-767.
[17] Sun H, Samarghandi A, Zhang N,et al.Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor[J].Arterioscler Thromb Vasc Biol,2012,32(7):1585-1595.
[18] Boekholdt SM,Arsenault BJ,Mora S,et al. Association of LDL cholesterol,non-HDL cholesterol,and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins:a meta-analysis[J].JAMA,2012,307(12):1302-1309.
[19] Chapman MJ, Ginsberg HN, Amarenco P,et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease:evidence and guidance for management[J]. Eur Heart J,2011,32(11):1345-1361.
[20] Jänis MT,Tarasov K,Ta HX,et al. Beyond LDL-C lowering:distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9(PCSK9)deficiency[J].Atherosclerosis,2013,228(2):380-385.
[21] Kwakernaak AJ, Lambert G, Dullaart RP.Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins[J].Clin Biochem,2014,47(7-8):679-682.
[22] Lambert G, Jarnoux AL, Pineau T,et al. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9:lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor [J].Endocrinology,2006,147(10):4985-4995.
[23] Tavori H, Fan D, Blakemore JL,et al. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor:evidence for a reciprocal regulation[J]. Circulation,2013,127(24):2403-2413.
[24] Shojaee-Moradie F,Ma Y,Lou S,et al. Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol[J]. Diabetes,2013,62(12):4063-4069.
[25] le May C, Kourimate S, Langhi C,et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia[J].Arterioscler Thromb Vasc Biol,2009,29(5):684-690.
[26] Rashid S, Tavori H, Brown PE,et al. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms[J].Circulation,2014,130(5):431-441.
[27] Levy E, Ben Djoudi Ouadda A, Spahis S,et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells[J].Atherosclerosis,2013,227(2):297-306.
[28] Olofsson SO,Borén J. Apolipoprotein B secretory regulation by degradation[J].Arterioscler Thromb Vasc Biol,2012,32(6):1334-1338.
[29] Fitzgerald K,Frank-Kamentsky M,Shulga-Morskaya S,et al.Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9(PCSK9)and the concentration of serum LDL cholesterol in healthy volunteers:a randomised, single-blind, placebo-controlled, phase 1 trial[J]. Lancet,2014,383(9911):60-68.
[30] McKenney JM.Understanding PCSK9 and anti-PCSK9 therapies[J].J Clin Lipidol,2015,9(2):170-186.
[31] Kühnast S, van der Hoorn JW, Pieterman EJ,et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[J]. J Lipid Res,2014,55(10):2103-2112.
[32] Almontashiri NA, Vilmundarson RO, Ghasemzadeh N,et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies[J]. PLoS One,2014,9(9):e106294.
[33] Stawowy P.Proprotein convertases in atherogenesis[J]. Curr Opin Lipidol, 2015,26(4):338-344.
[34] Schwartz GG,Bessac L,Berdan LG,et al.Effect of alirocumab, a monoclonal antibody to PCSK9,on long-term cardiovascular outcomes following acute coronary syndromes:rationale and design of the ODYSSEY outcomes trial[J].Am Heart J,2014,168(5):682-689.
相似文献/References:
[1]吴文芳,赵新湘,闫东.颈动脉斑块的核磁共振成像检测在冠心病中研究及应用进展[J].心血管病学进展,2016,(1):91.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.024]
WU Wenfang,ZHAO Xinxiang,YAN Dong.Magnetic Resonance Imaging Detection of Carotid Artery Plaque in
Coronary Artery Disease and Its Application[J].Advances in Cardiovascular Diseases,2016,(1):91.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.024]
[2]阎萌,田芳,综述,等.程序性坏死与动脉粥样硬化[J].心血管病学进展,2016,(2):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
YAN Meng,TIAN Fang,TIAN Ye.Necroptosis and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(1):139.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.011]
[3]许利冬,综述,李为民,等.左主干解剖形态与左冠状动脉粥样硬化研究新进展[J].心血管病学进展,2016,(2):173.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.020]
XU Lidong,LI Weimin.New Progress Between Left Main Coronary Anatomy and Left Coronary
Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(1):173.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.020]
[4]陈芡茹,综述,叶飞,等.心血管疾病治疗新目标:脂蛋白相关磷脂酶A2[J].心血管病学进展,2016,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
CHEN Qianru,YE Fei.Novel Therapeutic Target of Cardiovascular Disease:Lipoprotein Associated
Phospholipase A2[J].Advances in Cardiovascular Diseases,2016,(1):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
[5]蔡鹏,综述,王旭开,等.胰岛素清除率下降机制及其对大血管损伤作用的研究进展[J].心血管病学进展,2016,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.020]
CAI Peng,WANG Xukai.Mechanism and Large Vascular Injury Effect of Insulin Clearance Decrease[J].Advances in Cardiovascular Diseases,2016,(1):292.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.020]
[6]刘欢,刘润冬,综述,等.血管内皮功能的评价及其临床价值[J].心血管病学进展,2016,(4):426.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.026]
LIU Huan,LIU Rundong,WANG Hongyu.Evaluation of Vascular Endothelial Function and Its Clinical Value[J].Advances in Cardiovascular Diseases,2016,(1):426.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.026]
[7]胥雪莲,何川.炎症与动脉粥样硬化[J].心血管病学进展,2015,(5):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
XU Xuelian,HE Chuan.Inflammation and Atherosclerosis[J].Advances in Cardiovascular Diseases,2015,(1):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
[8]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(1):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[9]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(1):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[10]于洋杰 谢坤 高秀芳 施海明 李勇.非高密度脂蛋白胆固醇可以替代低密度脂蛋白胆固醇吗？[J].心血管病学进展,2021,(1):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
YU Yangjie,XIE Kun,GAO Xiufang,et al.Can LDL-C be Replaced by non-HDL-C[J].Advances in Cardiovascular Diseases,2021,(1):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]